Biofire Defense LLC

Biofire Defense LLC, a Salt Lake City-based manufacturer of molecular diagnostic systems and in vitro diagnostic products, operates as a prime contractor delivering FilmArray and RAZOR Mk II diagnostic platforms, multiplex molecular analyzer systems, test panels, reagents, and associated maintenance services to the Defense Department, Department of State, National Institutes of Health, and other federal agencies on full-and-open competition with no set-aside posture.

Biofire Defense competes predominantly as a prime contractor, accounting for 100 percent of its recent award portfolio. The company holds manufacturing-focused NAICS designations (Medicinal and Botanical Manufacturing 4,178 awards; Analytical Laboratory Instrument Manufacturing 733 awards) and product service codes anchored in diagnostics (In Vitro Diagnostic Substances, Reagents, Test Kits and Sets 351 awards; Drugs and Biologicals 3,811 awards). Biofire Defense has operated as a registered federal contractor since 2001.

Customer concentration is heavily skewed toward two agencies by dollar value. The top customer by potential value is the Department of the Army Acquisition Support Center Joint Program Executive Office for Chemical and Biological Defense, which anchors $391.6 million across 216 awards—representing 53 percent of combined potential value in the source. The second-ranking customer by dollars, the Department of State Bureau of Medical Services, carries $35.9 million across 24 awards. By award count, the Defense Logistics Agency Troop Support Medical dominates with 4,403 awards valued at $10.3 million, reflecting high-volume, low-dollar-value micro-purchases and consumable reorders. The top five customers by count account for 85 percent of awards; the top five by dollars account for 66 percent of combined potential value. This concentration signals reliance on Joint PEO Chemical and Biological Defense for strategic, high-value diagnostic modernization work and broad, transactional relationships with logistics and bureau-level medical buyers across State and Defense.

Biofire Defense holds four active parent vehicles. The largest by task-order volume is an Indefinite Delivery Contract (SPE2D015D0008) with 3,307 task orders carrying $3.2 million combined potential value—indicative of frequent, small consumable orders. The company also manages an IDC (SPM2D010D0003) with 853 task orders worth $2.4 million and a higher-value IDC (W911QY13D0080) supporting Joint PEO Chemical and Biological Defense with 178 task orders totaling $127.3 million. Beyond these, Biofire Defense sits on the GSA Multiple Award Schedule and federal supply schedules, with 107 MAS task orders carrying $6.2 million and 71 GSA supply-schedule orders valued at $786 thousand.

Recent activity shows volatility: 111 awards in 2022, declining to 79 in 2023, rebounding to 99 in 2024, then dropping to 81 in 2025 and 17 to date in 2026. Thirteen awards totaling $24.9 million in potential value reach ultimate completion within the next twenty-four months, representing moderate recompete exposure concentrated on sustainment and supply contracts rather than new platform development.

Representative prime work spans diagnostic equipment procurement, test panel supply, and service sustainment. A $4.85 million Defense Health Agency IDC (October 1, 2025–September 30, 2030) procures equipment lease and reagent supply for the Madigan Army Medical Center Department of Pathology, with a $968 thousand delivery order issued October 1, 2025. A $5.42 million Defense Health Agency purchase order (October 1, 2025–September 30, 2030) covers molecular PCR infectious disease testing services. A $4.5 million State Department single-award BPA (March 5, 2025–March 4, 2027) supplies FilmArray panels and control kits for embassy medical testing, with 35 call orders issued through December 2025 ranging from $2,489 to $20,480. An $8.33 million Other Transaction IDV (Department of the Army, August 1, 2025) validates the Environmental Film Array NGDS Sentinel Panel for the Biofire Spotfire system. A $1.65 million NIH Clinical Center IDC (January 8, 2025–September 30, 2026) procures Biofire reagents. A $3.5 million Defense Health Agency purchase order (September 30, 2024–September 29, 2029) covers molecular diagnostic kits. A $1.95 million Joint PEO Chemical and Biological Defense delivery order (April 1, 2024–August 18, 2025) updates security classification guides for the Next Generation Diagnostics System.

Across SCI-reportable federal service contracts—a partial view covering contracts above $150,000 threshold and excluding goods and products—Biofire Defense reported $7.1 million in invoiced prime revenue across FY2022–FY2024. Activity was sparse in FY2022 ($148 thousand, 1.8 FTEs) and FY2023 ($0), then jumped to $6.9 million across 30.5 FTEs in FY2024. Government-paid hourly rates on service contracts ran from a low 10th percentile of $20.08/hr to a median of $81.67/hr and a high 90th percentile of $236.90/hr, indicating a mix of entry-level labor and highly specialized technical delivery. Across SCI-reportable prime contracts, subcontractors accounted for 8 percent of total hours, with one named subcontractor appearing in the dataset—a lean delivery posture reflecting Biofire Defense's proprietary manufacturing and direct labor model.

Biofire Defense subcontracts to larger primes on specialized diagnostic work. Named prime contractors include Prism Maritime, Inc. (four awards for FilmArray NGDS Sentinel and Warrior Panels under CBRND support services and Seaport NXG, ranging from September 2024 to January 2026) and KBR Services, LLC (one January 2026 award for R90 Panel medical supplies under the Medical Support Services Iraq contract). These sub-arrangements position Biofire Defense as a specialized diagnostics supplier embedded in larger defense-support programs rather than as a feeder to prime integrators.

Idaho Technology manufacturers analytical laboratory instruments and develops, and sells the fastest high-speed air thermal, the R.A.P.I.D. System, RapidCycler and HR-1.